About Lunit
Lunit is a company based in Seoul (South Korea) founded in 2013. It operates as a AI-as-a-Service. Lunit has raised $133.16 million across 7 funding rounds from investors including Guardant Health, NH Investment & Securities and LG CNS. The company has 320 employees as of December 31, 2024. Lunit has completed 1 acquisition, including Volpara Health. Lunit offers products and services including Cancer Screening AI and Cancer Treatment AI. Lunit operates in a competitive market with competitors including Median, Oxipit, Dxcover, SimBioSys and Aidence, among others.
- Headquarter Seoul, South Korea
- Employees 320 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lunit Inc.
-
Annual Revenue
$57.53 M (USD)53.43as on Dec 31, 2025
-
Net Profit
-$32.27 M (USD)43.43as on Dec 31, 2025
-
EBITDA
-$40.66 M (USD)-53.5as on Dec 31, 2024
-
Total Equity Funding
$133.16 M (USD)
in 7 rounds
-
Latest Funding Round
$61 M (USD), Series C
Nov 25, 2021
-
Investors
Guardant Health
& 18 more
-
Employee Count
320
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lunit
Lunit is a publicly listed company on the KRX with ticker symbol 328130 in South Korea, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lunit
Lunit offers a comprehensive portfolio of products and services, including Cancer Screening AI and Cancer Treatment AI.
AI is used for early-stage cancer detection.
AI predicts immunotherapy response for better efficacy.
People of Lunit
Unlock access to complete
Unlock access to complete
Funding Insights of Lunit
Lunit has successfully raised a total of $133.16M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $61 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lunit
Lunit has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Guardant Health, NH Investment & Securities and LG CNS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on tech and life sciences startups.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
BrightEdge is focused on impact investment in cancer care innovation.
|
Locked | Locked | Locked |
Investor details for Lunit
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lunit
Lunit has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Volpara Health.
Investment portfolio details for Lunit
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based clinical decision support and cancer diagnosis tool for providers
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Lunit
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lunit
Detailed financials for Lunit
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lunit Comparisons
Peer comparison for Lunit
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lunit
Lunit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Median, Oxipit, Dxcover, SimBioSys and Aidence, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical imaging software and services are provided for clinical trials.
|
|
| Locked | Locked | Locked |
Artificial intelligence is used for analyzing medical images in healthcare.
|
|
| Locked | Locked | Locked |
AI-powered device developed for early brain tumor diagnosis.
|
|
| Locked | Locked | Locked |
AI-based cancer diagnosis tools are provided for healthcare professionals.
|
|
| Locked | Locked | Locked |
Medical images are analyzed using deep learning for radiologists.
|
Detailed competitors of Lunit
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lunit
Complete news archive for Lunit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lunit
Lunit was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Lunit is headquartered in Seoul, South Korea.
Lunit is a funded company, having raised a total of $133.16M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lunit is 320.
Annual revenue of Lunit is $57.53M as on Dec 31, 2025.
Lunit is engaged in creating AI-driven solutions for cancer screening and treatment. The company operates in the healthcare sector, specializing in medical technology. Its AI tools are designed for early detection of cancers to enable timely intervention and for predicting immunotherapy responses to enhance treatment efficacy. Lunit collaborates with global research and business partners across over 50 countries, supporting precision oncology and expanding access to AI in public healthcare systems.
Lunit offers Cancer Screening AI and Cancer Treatment AI.
Yes, Lunit is publicly traded on KRX under the ticker symbol 328130.
Lunit has made 1 acquisition, including Volpara Health.
Lunit has 19 investors. Key investors include Guardant Health, NH Investment & Securities, LG CNS, Shinhan Financial Group, and Health Quest Capital.
The ticker symbol of Lunit is 328130 on KRX.